Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 28/03/2023

Debbie Rigby rounds up the latest in research news Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk A systematic review and meta-analysis was performed to investigate the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk. A 1- or 3-month abbreviated DAPT

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Research Roundup

Previous Feminised workforce opting for part-time roles

Next 'Strong supporter’ of pharmacy named NSW Health Minister

MENU

ajp.com.au

Previous Feminised workforce opting for part-time roles

Next 'Strong supporter’ of pharmacy named NSW Health Minister

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.